Item 7.01 Regulation FD Disclosure.

On April 14, 2021, Taysha Gene Therapies, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company's website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report.

Item 8.01 Other Events.

On April 14, 2021 the Company issued, and posted to its website, a press release entitled "Taysha Gene Therapies Announces New Data on Multiple Preclinical Programs and Upcoming R&D Day." The full text of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



           Exhibit
             No.                        Description

           99.1        Corporate presentation, dated April 14, 2021.

           99.2        Press release, dated April 14, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses